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Adrenocortical Carcinoma; Adrenal Tumor 
Note 
Adrenocortical carcinoma is a rare malignant neoplasm 
of adrenal glands, which most often presents without 
any hormonal symptoms. The most common clinical 
presentation of patients with hormone-secreting 
adrenocortical carcinoma is that of Cushing’s 
syndrome.  
Other hormonal hypersecretion syndromes associated 
with adrenocortical carcinoma include virilization 
(from androgen-producing tumors), feminization 
(estrogen-producing tumors), and hyperaldosteronism.  
Multiple hormones may be produced by a single tumor, 
causing a mixed clinical picture. In children, 
virilization is more common because carcinomas have 
a greater tendency to be presented with a hormonal 
syndrome. 
Clinics and pathology 
Etiology 
Adrenal cancer may present as part of rare hereditay 
syndromes such as Wiedemann-Beckwith syndrome 
(WBS) linked to 11p15.5 or the Li-Fraumeni syndrome 
(LFS), associated with germline mutations of the TP53 
gene, on 17p. Sometimes carcinomas develop in 
children with congenital adrenal hyperplasia (CAH) 
that is caused  
most frequently by mutations in the CYP21B gene. 
 
Epidemiology 
Adrenal cancer is a rare malignancy representing only 
0.05% and 0.2% of all cancers worldwide. Women tend 
to develop functional adrenal cortical carcinomas more 
commonly than men. Men develop non-functional 
malignant adrenal tumors more often than women.  
There is a bimodal distribution in terms of age: young 
children less than 5 years old, and adults in their 30s 
and 40s. In Brazil, the incidence of carcinomas is three 
times more than the international rate. 
Pathology 
Grading and staging:  
Stage I: disease confined to the adrenal gland without 
local invasion or distant metastases and the greatest 
tumor dimension less than 5cm. 
Stage II: same as stage I but the greatest tumor 
dimension is greater than 5 cm. 
Stage III: local invasion that does not involve adjacent 
organs or regional lymph nodes. 
Stage IV: distant metastases or invasion into adjacent 
organs plus regional lymph nodes. 
Treatment 
Treatment for adrenocortical carcinomas is complete 
surgical resection; these tumors do not respond well to 
chemotherapy. Mitotane may be used as a chronic 
treatment in non-cured cases or prophylactically. Other 
medications (e.g. ketoconazole, metyrapone, 
aminoglutethimide) may be given to reduce production 
of cortisol and other adrenal steroids that is respon ible 
for many of symptoms. 
 










Extremely poor prognosis, with a survival rate at 20% 
at five years for stage I-II disease.Poor prognostic 
indicators include: age at diagnosis, tumor size, distant 
metastases, invasion of vessels, capsule, or adjacent 
organs, and tumor necrosis. Pediatric patients with a 
hormonal syndrome are considered to have a better 
prognosis because the associated signs and symptoms 
can make the cancer diagnosis easier leading to earlier 
surgical intervention 
Cytogenetics 
Morphological Cytogenetics  
Only a few karyotyping studies has been performed. 
Chromosomal analysis revealed a modal number of 61 
with consistent structural abnormalities of add(3)(q11), 
add(9)(p11), and add(16)(ql1) in one case of adult 
carcinoma and the karyotype 46, XX, t(4;11)(q35;p13) 
in the another one. Karyotyping of short-term cultured 
cells from an 11-cm adrenocortical carcinoma in a 3.5-
year-old girl revealed the very complex karyotype 
46,XX, inv(9)(p11q12)c/[2]/56-57,XX, +2, +4, +5, +7, 
+8, inv(9)c, +10, +add (13)(p11), +14, +15, +19, +20, 
+20, +mar[cp19]. 
Molecular Cytogenetics  
Fluorescent in situ hybridization (FISH) studies of 
carcinomas showed increasing genome instability in 
carcinoma progression. Loss of heterozygosity (LOH) 
studies identified allelic losses on chromosomes 11p, 
11q, 13q, and 17p. The LOH on 2p16 is strongly 
associated with the malignant phenotype. 
Several studies were reported in carcinomas with 
comparative genomic hybridization (CGH). DNA 
sequence copy number gains were identified on 
chromosomes 4, 5, 9q, and 12q and losses on 
chromosomes 17p, 1p, 2q, 11q, and 9p. All studies 
showed that the number of genomic changes is closely 
correlated with tumor behavior. In adenomas, small 
tumors contain a small or zero number of chromosomal 
imbalances, and a number of changes increases in 
larger adenomas and then considerably increases in 
carcinomas. Of adenomas, the most common 
alterations were gains of 4q, 17p, 17q and 9q32-qter. 
Two CGH studies of childhood adrenal tumors showed 
extensive genetic alterations both in benign and 
malignant tumors. The copy number changes are 
distinctly different to those seen in adult tumors thus 
possibly reflecting different genetic background for 
these tumors. High-level amplification of 9q34 was 
very common. 
Genes involved and proteins 
Note 
A number of genes are implicated in tumor progression  
from adrenal adenoma to carcinoma; they include both 
oncogenes and tumor suppressor genes. Progression 
from adenoma to carcinoma involves a monoclonal 
proliferation of cells, which, together with other 
defects, have undergone rearrangements of the 
chromosomal locus 11p15.5 associated with IGF II 
hyperexpression and abrogation of expression of the 
CDKN1C and H19 genes. TP53 is involved in 
progression to carcinoma in a subset of patients. In 
childhood ADCC, 50% of children carried germline 
mutations of TP53. Deletions of the ACTH receptor 
gene have been recently found in undifferentiated 
adenomas and in aggressive adrenocortical carcinomas 
although the frequency of ACTH receptor deletion 
needs to be more fully examined. Other key oncogenes 
and tumor suppressor genes remain to be identified 
although the chromosomal loci that harbor them were 
identified at 17p, 1p, 2p16, 11q13, and 9p for tumor 
suppressor genes and chromosomes 4, 5, 9q, and 12 for
oncogenes. The 11q13 region harbors the MEN1 gene, 
however mutations of the gene were not found in 
adrenal tumors. 
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